Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 20:12:33时区推断·⟳ 抓取 20:18:15·⚡ 决策 08-04 20:37:43 +19m28s·84.1 天前
CEL-SCI发表Multikine头颈癌生物标志物研究并准备212人确认性注册研究
研究显示低或零PD-L1且N0人群中5年总生存率为73.4%对45.8%，HR为0.34，但这是已完成研究的标志物分层结果。
📄 原文Investing.com↗ 原文
CEL-SCI publishes study on Multikine cancer treatment biomarkers
BofA says this memory stock could double. Here are 5 reasons why VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM)…
不做 CEL-SCI（CVM.US）
不做：论文分层数据利好但无批准、无销售、核心注册研究仍未完成，盘前已涨约7.8%，更像小盘生物科技波动而非可量化商业化催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司此前已披露FDA接受筛选标准并允许开展212人确认性注册研究，说明本次研究结论并非全新注册路径。
- 媒体转述CEL-SCI发表Oral Oncology论文，披露73.4%对45.8%五年生存率和212人确认性注册研究计划。市场反应:CVM盘前报价约1.25美元，较前收上涨7.76%。
关键理由
- 研究显示低或零PD-L1且N0人群中5年总生存率为73.4%对45.8%，HR为0.34，但这是已完成研究的标志物分层结果。
- Multikine仍未获FDA或其他监管机构批准，公司尚需启动并完成212人确认性注册研究，当前没有商业化收入增量。
- CVM盘前约1.25美元、较前收1.16美元涨7.76%，市值约2185万美元，市场已有反应但基本面仍停留在临床验证阶段。
主要风险
- 此前Phase 3总体人群曾未达主要终点，后续确认性研究、融资和监管风险仍高。
- 公司2026年5月曾以每股1.20美元发行600万股，低价融资和摊薄压力会压制单纯论文催化的持续性。
反向证据
- 做多前查反向 · 来源 web · 日期 2024-12-12 · 影响 weakens
公司此前披露Phase 3总体ITT人群未达主要终点，当前论文属于分层选择后的验证依据。
检索:CEL-SCI Multikine Phase 3 head and neck cancer failed primary endpoint 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-06 · 影响 weakens
公司近期低价发行普通股融资，若借论文催化上涨仍可能面对再融资折价预期。
检索:CEL-SCI 2026 10-Q common stock offering 6,000,000 shares 1.20 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中与本次Multikine论文相关的有效投研证据。
检索:CEL-SCI Multikine biomarker Oral Oncology 73.4 45.8 confirmatory registration study
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,054 字
BofA says this memory stock could double. Here are 5 reasons why
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced the publication of its clinical trial study in the journal Oral Oncology, identifying biomarkers for patient selection in its Multikine cancer treatment program, according to a press release statement.
The peer-reviewed study identified low and zero tumor PD-L1 expression (TPS <10%) and absence of lymph node involvement (N0) as biomarkers for selecting patients who may benefit from Multikine administered before surgery. The company stated these biomarkers will form the foundation for patient selection in its upcoming Confirmatory Registration Study.
In the biomarker-selected patient population, patients receiving Multikine treatment before surgery followed by standard care achieved a 73.4% five-year overall survival rate compared with 45.8% for patients receiving surgery followed by standard care alone, corresponding to a hazard ratio of 0.34 (p=0.0012). The study also reported a 49% reduction in the risk of disease progression or death (PFS hazard ratio 0.51; p=0.0197) in the same patient population.
Multikine is an investigational immunotherapy administered before surgery for newly diagnosed, previously untreated, locally advanced head and neck cancer. The treatment has not been approved by the FDA or any regulatory agency.
CEL-SCI is preparing to commence enrollment in a global 212-patient Confirmatory Registration Study evaluating Multikine in head and neck oral cancer patients with low and zero PD-L1 tumor expression and no lymph node involvement. The trial is designed with approximately 97% statistical power to confirm the previously observed overall survival benefit, the company stated.
Multikine has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced the publication of its clinical trial study in the journal Oral Oncology, identifying biomarkers for patient selection in its Multikine cancer treatment program, according to a press release statement.
The peer-reviewed study identified low and zero tumor PD-L1 expression (TPS <10%) and absence of lymph node involvement (N0) as biomarkers for selecting patients who may benefit from Multikine administered before surgery. The company stated these biomarkers will form the foundation for patient selection in its upcoming Confirmatory Registration Study.
In the biomarker-selected patient population, patients receiving Multikine treatment before surgery followed by standard care achieved a 73.4% five-year overall survival rate compared with 45.8% for patients receiving surgery followed by standard care alone, corresponding to a hazard ratio of 0.34 (p=0.0012). The study also reported a 49% reduction in the risk of disease progression or death (PFS hazard ratio 0.51; p=0.0197) in the same patient population.
Multikine is an investigational immunotherapy administered before surgery for newly diagnosed, previously untreated, locally advanced head and neck cancer. The treatment has not been approved by the FDA or any regulatory agency.
CEL-SCI is preparing to commence enrollment in a global 212-patient Confirmatory Registration Study evaluating Multikine in head and neck oral cancer patients with low and zero PD-L1 tumor expression and no lymph node involvement. The trial is designed with approximately 97% statistical power to confirm the previously observed overall survival benefit, the company stated.
Multikine has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。